271,720 Shares in Prothena Corporation plc $PRTA Purchased by Penbrook Management LLC

Penbrook Management LLC purchased a new stake in shares of Prothena Corporation plc (NASDAQ:PRTA) in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 271,720 shares of the biotechnology company’s stock, valued at approximately $2,641,000. Prothena accounts for 2.0% of Penbrook Management LLC’s holdings, making the stock its 12th biggest position. Penbrook Management LLC owned approximately 0.50% of Prothena as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the stock. Tower Research Capital LLC TRC grew its position in shares of Prothena by 571.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 12,709 shares of the biotechnology company’s stock valued at $77,000 after acquiring an additional 10,815 shares during the period. ProShare Advisors LLC bought a new stake in shares of Prothena in the 4th quarter worth approximately $100,000. PDT Partners LLC purchased a new position in Prothena in the fourth quarter valued at approximately $108,000. Voleon Capital Management LP purchased a new position in Prothena in the second quarter valued at approximately $113,000. Finally, DRW Securities LLC bought a new position in Prothena during the fourth quarter valued at $114,000. Hedge funds and other institutional investors own 97.08% of the company’s stock.

Insider Transactions at Prothena

In related news, major shareholder William P. Scully acquired 20,000 shares of the company’s stock in a transaction that occurred on Tuesday, June 16th. The shares were acquired at an average price of $7.90 per share, with a total value of $158,000.00. Following the acquisition, the insider owned 756,000 shares of the company’s stock, valued at approximately $5,972,400. This trade represents a 2.72% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Over the last 90 days, insiders bought 345,000 shares of company stock worth $3,097,250. Corporate insiders own 10.40% of the company’s stock.

Analyst Ratings Changes

A number of research firms have issued reports on PRTA. Citizens Jmp raised their target price on Prothena from $19.00 to $20.00 and gave the stock a “market outperform” rating in a research report on Friday, May 8th. Citigroup reaffirmed an “outperform” rating on shares of Prothena in a research report on Friday, May 8th. Wall Street Zen upgraded Prothena from a “hold” rating to a “buy” rating in a research note on Saturday, June 6th. Weiss Ratings raised Prothena from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday. Finally, Stifel Nicolaus set a $19.00 price objective on shares of Prothena in a report on Friday, March 13th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Prothena currently has an average rating of “Moderate Buy” and a consensus price target of $23.75.

Prothena Trading Down 1.4%

Prothena stock opened at $9.27 on Friday. The firm has a 50 day simple moving average of $9.74 and a 200 day simple moving average of $9.52. Prothena Corporation plc has a 1-year low of $5.83 and a 1-year high of $11.80. The firm has a market capitalization of $485.28 million, a price-to-earnings ratio of -3.29, a P/E/G ratio of 1.50 and a beta of -0.25.

Prothena (NASDAQ:PRTA) last posted its earnings results on Thursday, May 7th. The biotechnology company reported $0.60 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.31) by $0.91. The firm had revenue of $51.08 million for the quarter, compared to the consensus estimate of $0.81 million. Prothena had a negative return on equity of 43.44% and a negative net margin of 260.92%. On average, equities research analysts forecast that Prothena Corporation plc will post 0.18 EPS for the current year.

About Prothena

Prothena Corporation plc is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for neurodegenerative and rare diseases driven by misfolded proteins. The company’s research focuses on immunotherapies and small molecules designed to target and clear disease-causing protein aggregates. Prothena leverages proprietary protein engineering and antibody discovery platforms to advance candidates through preclinical and clinical stages.

The company’s most advanced program is an antibody targeting aggregated alpha-synuclein for the potential treatment of Parkinson’s disease, currently in mid-stage clinical trials.